Gene Therapy For Rare Disease Market
According to Intent Market Research, the Gene Therapy For Rare Disease Market is expected to grow from USD 2.5 billion in 2023 at a CAGR of 8.1% to touch USD 4.3 billion by 2030. The Gene Therapy For Rare Disease Market is dominated by key players such as, Bluebird Bio, Inc., Spark Therapeutics, Regeneron Pharmaceuticals, Inc., Sangamo Therapeutics, Inc., and CRISPR Therapeutics AG.